2型糖尿病对接受袖状胃切除术的多囊卵巢综合征患者的影响
这项单中心、两臂、前瞻性队列研究纳入2020年1月至2023年8月因肥胖拟行袖状胃切除术的329例多囊卵巢综合征女性,随访术后1年。合并2型糖尿病组(98例)较无糖尿病组(149例)代谢特征更重但生殖特征更轻,术后1年规律月经恢复比例两组相似(85% vs 87%,P=0.758)。
要点
- 合并2型糖尿病组胰岛素抵抗、糖耐量异常、血脂异常及非酒精性脂肪性肝病更重。
- 合并2型糖尿病组总睾酮、黄体生成素与卵泡刺激素比值及多囊卵巢形态比例更低。
- 术后1年两组规律月经恢复比例相似(85% vs 87%,P=0.758),糖尿病未减弱月经恢复。
核心结论
- 对于接受袖状胃切除术的肥胖多囊卵巢综合征患者,合并2型糖尿病与代谢特征加重但生殖特征较轻相关,且术后至多1年未减弱规律月经的恢复。
研究设计与样本
- 单中心、两臂、前瞻性队列研究,纳入2020年1月至2023年8月于大学附属医院因肥胖拟行袖状胃切除术的多囊卵巢综合征女性共329例,术后随访1年。
主要发现
- 控制混杂因素后,PCOS+2型糖尿病组(n=98)较PCOS组(n=149)非酒精性脂肪性肝病活动度评分更高(4.31±1.15 vs 3.52±1.42,P<0.001)。
- PCOS+2型糖尿病组较PCOS组总睾酮更低(1.63±0.69 vs 1.82±0.76,P=0.045)。
- PCOS+2型糖尿病组较PCOS组黄体生成素与卵泡刺激素比值中位数更低(1.48 vs 1.68,P=0.030)。
- PCOS+2型糖尿病组较PCOS组多囊卵巢形态比例更低(88% vs 96%,P=0.022),两组Rotterdam分型差异有统计学意义(P=0.009)。
- PCOS+2型糖尿病组较PCOS组情绪性进食程度更低(P=0.001),其余心理特征组间无显著差异;术后1年规律月经比例两组相似(85% vs 87%,P=0.758)。
局限性
- 袖状胃切除术后多囊卵巢综合征的预后评估主要聚焦于月经结果,而非疾病的完整缓解评估。
- 作者指出需要更全面评估2型糖尿病对袖状胃切除术后多囊卵巢综合征患者预后影响的高质量研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Does the concurrent type 2 diabetes mellitus (T2DM) aggravate the features and prognosis of PCOS in patients undergoing sleeve gastrectomy (SG)? SUMMARY ANSWER: For patients undergoing SG with obesity, concurrent T2DM is associated with aggravated metabolic but milder reproductive features of PCOS and did not attenuate the resumption of regular menstruation for up to 1 year after surgery. WHAT IS KNOWN ALREADY: Women with T2DM have an increased risk of PCOS. However, whether concurrent T2DM further increases the disease burden and treatment difficulty of PCOS in patients with obesity requires further investigation. STUDY DESIGN, SIZE, DURATION: This was a single-center, two-arm, prospective, cohort study enrolling a total of 329 women with PCOS and scheduled for SG because of obesity at an university-affiliated hospital between January 2020 and August 2023, with a 1-year follow-up after surgery. PARTICIPANTS/MATERIALS, SETTING, METHODS: Comparisons were made between patients with T2DM (PCOS+T2DM) and without (PCOS) to examine the impact of T2DM on the metabolic, reproductive, and psychological features of PCOS. The follow-up data of weight loss and menstruation were analyzed to determine the impact of T2DM on PCOS prognosis for up to 1 year after SG. MAIN RESULTS AND THE ROLE OF CHANCE: After controlling for confounders, patients in the PCOS+T2DM group (n = 98) showed more severe insulin resistance, glucose intolerance, dyslipidemia, and non-alcoholic fatty liver disease (NAFLD) (NAFLD activity score 4.31 ± 1.15 versus 3.52 ± 1.42, P < 0.001) than those in the PCOS group (n = 149). In addition, the PCOS+T2DM group had a lower level of total testosterone (1.63 ± 0.69 versus 1.82 ± 0.76, P = 0.045), a lower ratio between luteinizing hormone and follicle-stimulating hormone (median 1.48 versus 1.68, P = 0.030), and a lower proportion of patients with polycystic ovarian morphology (88% versus 96%, P = 0.022) than the PCOS group. As a result, the two groups differed significantly in terms of the Rotterdam classification of PCOS (P = 0.009). No significant difference was detected by group in the psychological features of PCOS except a lower degree of emotional eating in the PCOS+T2DM group (P = 0.001). Although the PCOS+T2DM group took longer to resume regular menstruation after SG (P = 0.037), the two groups had similar proportions of patients with regular menstruation (85% versus 87%, P = 0.758) 1 year after SG, which was further confirmed by subgroup analyses by body mass index. LIMITATIONS, REASONS FOR CAUTION: The prognosis of PCOS after SG mainly focused on the results of menstruation rather than a complete evaluation of the remission of the disease. WIDER IMPLICATIONS OF THE FINDINGS: Our study showed that, for patients with obesity, concurrent T2DM is associated with aggravated metabolic but milder reproductive features of PCOS and did not attenuate the resumption of regular menstruation for up to 1 year after surgery. Our study also highlights the need for high-quality studies with a more comprehensive evaluation of the impact of T2DM on the prognosis of patients with PCOS after SG. STUDY FUNDING/COMPETING INTEREST(S): This study was funded by the National Natural Science Foundation of China Grants (82100853), the Natural Science Foundation of Shandong Province of China (ZR2021QH028), and the Clinical Research Project of Shandong University (2020SDUCRCC024). The authors have no conflicts of interest. TRIAL REGISTRATION: Chinese Clinical Trial Registry with No. ChiCTR1900026845.
引用
- Zhu T, Zhao Y, Bi X, et al. The impact of type 2 diabetes on polycystic ovary syndrome in patients undergoing sleeve gastrectomy. Hum Reprod. 2024. PMID: 39008821. doi:10.1093/humrep/deae159
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。